Expression and significance of COX-2, Ki-67 in colorectal carcinoma

doi:10.3877/cma.j.issn.2095-655X.2015.01.005

Abstract

Abstract:

Objective

To investigate the expression of cyclooxygenase 2 (COX-2) and transcription factor Ki-67 in colorectal carcinoma and their relationship with invasion and metastasis.

Methods

The expressions of COX-2 and Ki-67 were measured by immunohistochemical method staining in one hundred and twenty cases with colorectal carcinoma, forty cases with dysplasia tissue closely adjacent to carcinomas, and twenty cases with normal colorectal mucosa specimens.All the clinical and follow-up information were reviewed and evaluated.Fisher′s exat test, spearman′s correlation analysis, chi-square test were used to analyze the expressions of COX-2 and Ki-67.

Results

The expressions of COX-2 and Ki-67 in colorectal cancer tissues(78.3%, 73.3%, respectively) were obviously higher than those in adjacent tissues (25.0%, 35.0%, respectively) and normal mucosal tissues (10.0%, 20.0%, respectively) (COX-2: χ²=18.755, P<0.05; χ²=29.511, P<0.05.Ki-67: χ²=9.538, P<0.05; χ²=24.621, P<0.05). The differences were statistically significant .The expressions of COX-2 and Ki-67 in the high grade carcinoma were higher than those in low grade cancer(χ²=6.591, P<0.05; χ²=6.160, P<0.05), and the expression in advanced cancer was significantly raised compared with early cancer(χ²=4.925, P<0.05; χ²=6.317, P<0.05). The expression levels of COX-2 were correlated with lymph node metastasis(χ²=6.104, P<0.05; χ²=6.104, P<0.05). No significant differences were found in the expressions of Ki-67 among different types of high grade cancer had no significant difference(χ²=0.958, P>0.05), and there was no significant difference between colorectal dysplasia tissue and normal colorectal mucosa tissue.

Conclusions

The abnormal expressions of COX-2 and Ki-67 plays an important role in the genesis and development of colorectal carcinoma and may be responsible for the enhanced activity in tumor-induced neovascularization, invasion and metastasis.COX-2 and Ki-67 have positively expressive correlation and may serve as valuable indicators of biological behavior of colorectal carcinoma.COX-2 and Ki-67 may be the prognostic discriminators of colorectal carcinoma.

Key words: Colonic neoplasms, Cyclooxygenase 2, Ki-67, Prognosis

Zhaoyang Qin, Jingzhong Xu, Shenghua Tian, Quanhong Duan, Fenghe Hui. Expression and significance of COX-2, Ki-67 in colorectal carcinoma[J]. Chinese Journal of Diagnostics(Electronic Edition), 2015, 03(01): 19-23.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2015.01.005

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2015/V03/I01/19

Figures/Tables 2

References 16

[1]	孙跃,许刚,齐晓丽, 等. 骨形态发生蛋白2对体外培养结肠癌HT-29细胞增殖和凋亡的影响[J]. 济宁医学院学报, 2010, 33(2): 85-88.
[2]	Bosman FT,Carneiro F,Hruban RH, et al.WHO Classification of Tumours of the Digestive System[M]. Lyon: IARC Press, 2010.
[3]	Wang GP,Zhang H,Zhang ZF, et al.Clinical and pathological characteristics of intraductal proliferative lesions and coexist with invasive ductal carcinomas[J]. Chinses-German J Clin Oncol, 2013, 12(12): 574-580.
[4]	尹淑华,王付军. 增生性息肉与锯齿状腺瘤研究现状[J]. 济宁医学院学报, 2011, 34(2): 142-144.
[5]	杨志寅. 现代医学科学发展中的缺憾与思考[J/CD]. 中华诊断学电子杂志, 2013, 1(1): 1-7.
[6]	李世荣,田素丽,武子涛, 等. 序贯粪隐血试验在自然人群连续性大肠癌普查中的应用[J]. 世界华人消化杂志, 2004, 12(1): 137-139.
[7]	Liang YA,Li ZX,Wang GP.Expression of HIF-1α in breast cancer and precancerous lesions and the relationship to clinicopathological features[J]. Chinses-German J Clin Oncol, 2014, 13(1): 23-28.
[8]	王刚平,梁云爱,张作峰, 等. CD105标记微血管密度及HIF-1α在乳腺癌及癌前病变中的表达及意义[J/CD]. 中华临床医师杂志(电子版), 2013, 7(16): 30-34.
[9]	谢智惠,王蕾,吕庆, 等. COX-2与MVD在三阴性乳腺癌中的表达及相关性研究[J]. 南京医科大学学报(自然科学版), 2013, 33(10): 1410-1414.
[10]	阮玉凤,孙璟,吴方, 等. COX-2基因多态性与结直肠癌发病风险的关系研究[J]. 国际消化病杂志, 2013, 33(4)；260-263.
[11]	王刚平,张红,梁云爱, 等. β-tubulin-Ⅲ、E-cadherin和α-catenin在乳腺癌及癌前病变中的表达及意义[J/CD]. 中华诊断学电子杂志, 2013, 1(1): 57-61.
[12]	权继传,解亦斌,田艳涛. 国际抗癌联盟胃癌TNM分期系统第七版解读[J/CD]. 中华诊断学电子杂志, 2014, 2(1): 72-74.
[13]	叶斌,王西川,雷蕾, 等. p53和Ki67在结直肠癌中的表达及其临床意义[J]. 实用癌症杂志, 2013, 28(1): 42-44.
[14]	李铁灵,郭海峰,杜晓宏. 右半结肠癌中p53、Ki-67的表达及与分化程度及Ducks分期的关系[J]. 牡丹江医学院学报, 2007, 28(4): 17-19.
[15]	冯雯,曹亦军,张计训. 甲状腺癌中Ki67和survivin的表达及意义[J]. 实用医学杂志, 2009, 25(19): 3215-3218.
[16]	黄芳,钱国伟,刘俊杰, 等. ALDH1、EpCAM及Ki67 mRNA在大肠癌患者循环肿瘤细胞中的表达及意义[J]. 中国肿瘤外科杂志, 2013, 5(4): 235-238.

组织类型	例数	COX-2				Ki-67
组织类型	例数	＋	－	χ²值	P值	＋	－	χ²值	P值
结肠癌组织	120	94(78.3)	26(22.7)	---	---	88(73.3)	32(27.2)	---	---
癌旁异型组织	40	10(25.0)	30(75.0)	18.755^a	0.000	14(35.0)	26(65.0)	9.538^a	0.002
正常结肠黏膜组织	20	2(10.0)	18(90.0)	29.511^a	0.000	4(20.07)	16(80.0)	24.621^a	0.000

组织类型	例数	COX-2				Ki-67
组织类型	例数	＋	－	χ²值	P值	＋	－	χ²值	P值
结肠癌组织	120	94(78.3)	26(22.7)	---	---	88(73.3)	32(27.2)	---	---
癌旁异型组织	40	10(25.0)	30(75.0)	18.755^a	0.000	14(35.0)	26(65.0)	9.538^a	0.002
正常结肠黏膜组织	20	2(10.0)	18(90.0)	29.511^a	0.000	4(20.07)	16(80.0)	24.621^a	0.000

临床病理因素			例数	COX-2				Ki-67
临床病理因素			例数	＋	－	χ²值	P值	＋	－	χ²值	P值
低级别肠癌			74	50(67.6)	24(32.4)	0.332	0.564	46(62.2)	28(37.8)	0.015	0.904
?	高分化		26	16(61.5)	10(38.5)	?	?	14(53.8)	12(46.2)	?	?
?	中分化		48	34(70.8)	14(29.2)	?	?	32(66.7)	18(33.3)	?	?
高级别肠癌			46	44(95.7)	2(4.3)	1.960	0.375	42(91.3)	4(8.7)	0.958	0.619
?	黏液腺癌		14	14(100.0)	0(0)	?	?	14(100.0)	0(0)	?	?
?	印戒细胞癌		16	16(100.0)	0(0)	?	?	14(87.5)	2(12.5)	?	?
?	低分化腺癌		16	14(87.5)	2(12.5)	?	?	14(87.5)	0(12.5)	?	?
Dukes分期			?	?	?	0.124	0.724	?	?	0.003	0.954
?	(A＋B)期		56	36(64.3)	20(35.7)	?	?	34(60.7)	22(39.3)	?	?
?	?	A期	20	12(60.0)	8(40.0)	?	?	12(60.0)	8(40.0)	?	?
?	?	B期	36	24(66.7)	12(33.3)	?	?	22(61.1)	14(38.9)	?	?
?	(C＋D)期		64	58(90.6)	6(9.4)	0.013	0.910	54(84.4)	10(15.6)	1.659	0.198
?	?	C期	50	44(88.0)	6(12.0)	?	?	40(80.0)	10(20.0)	?	?
?	?	D期	14	14(100.0)	0(0)	?	?	14(100.0)	0(0)	?	?
浸润深度			?	?	?	4.925	0.027	?	?	6.317	0.012
?	早期癌		18	8(44.4)	10(56.6)	?	?	6(33.3)	12(66.7)	?	?
?	进展期癌		102	86(84.3)	16(15.7)	?	?	82(80.4)	20(19.6)	?	?
?	淋巴结转移		?	?	?	6.104	0.014	?	?	6.104	0.014
?	?	无	56	36(64.3)	20(35.7)	?	?	34(60.7)	22(39.3)	?	?
?	?	有	64	58(90.6)	6(9.4)	?	?	54(84.4)	10(15.6)	?	?

临床病理因素			例数	COX-2				Ki-67
临床病理因素			例数	＋	－	χ²值	P值	＋	－	χ²值	P值
低级别肠癌			74	50(67.6)	24(32.4)	0.332	0.564	46(62.2)	28(37.8)	0.015	0.904
?	高分化		26	16(61.5)	10(38.5)	?	?	14(53.8)	12(46.2)	?	?
?	中分化		48	34(70.8)	14(29.2)	?	?	32(66.7)	18(33.3)	?	?
高级别肠癌			46	44(95.7)	2(4.3)	1.960	0.375	42(91.3)	4(8.7)	0.958	0.619
?	黏液腺癌		14	14(100.0)	0(0)	?	?	14(100.0)	0(0)	?	?
?	印戒细胞癌		16	16(100.0)	0(0)	?	?	14(87.5)	2(12.5)	?	?
?	低分化腺癌		16	14(87.5)	2(12.5)	?	?	14(87.5)	0(12.5)	?	?
Dukes分期			?	?	?	0.124	0.724	?	?	0.003	0.954
?	(A＋B)期		56	36(64.3)	20(35.7)	?	?	34(60.7)	22(39.3)	?	?
?	?	A期	20	12(60.0)	8(40.0)	?	?	12(60.0)	8(40.0)	?	?
?	?	B期	36	24(66.7)	12(33.3)	?	?	22(61.1)	14(38.9)	?	?
?	(C＋D)期		64	58(90.6)	6(9.4)	0.013	0.910	54(84.4)	10(15.6)	1.659	0.198
?	?	C期	50	44(88.0)	6(12.0)	?	?	40(80.0)	10(20.0)	?	?
?	?	D期	14	14(100.0)	0(0)	?	?	14(100.0)	0(0)	?	?
浸润深度			?	?	?	4.925	0.027	?	?	6.317	0.012
?	早期癌		18	8(44.4)	10(56.6)	?	?	6(33.3)	12(66.7)	?	?
?	进展期癌		102	86(84.3)	16(15.7)	?	?	82(80.4)	20(19.6)	?	?
?	淋巴结转移		?	?	?	6.104	0.014	?	?	6.104	0.014
?	?	无	56	36(64.3)	20(35.7)	?	?	34(60.7)	22(39.3)	?	?
?	?	有	64	58(90.6)	6(9.4)	?	?	54(84.4)	10(15.6)	?	?

Please choose a citation manager

Content to export